Soligenix Collaborates with Intrexon on Promoting Monoclonal Antibody Therapy for Melioidosis
On May 1, 2013, Soligenix, Inc., a biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures announced its collaboration between Intrexon to develop a treatment for Melioidosis. Intrexon is a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function.
Melioidosis causes high rate of death. It is caused by Burkholderia pseudomallei.
With this agreement, Soligenix and Intrexon intend to develop and commercialize human monoclonal antibody therapies for new biodefense and infectious disease applications for Melioidosis . Intrexon will provide discovery and development of therapeutic antibody candidates, as well as optimize and expand production of human monoclonal antibodies targeting Melioidosis. Soligenix will undertake preclinical and clinical development, regulatory and government interactions, as well as the commercialization of therapeutic products.
In addition, Soligenix will use Intrexon’s platforms, such as protein engineering, genome engineering, and cell systems engineering .